FAQ

These will be FAQ for investors..please add:

1. What is BOT ?
Biotechnology company, expecting FDA approval for no-sweat drug in the next 8 days + Multiple Ph2 drug in the pipeline ( including anti microbial)

2. Is no sweat drug promising good revenue?

Yes, we have already sales in Japan , around 200 000 prescribtions per year

3. Any competition?
Yes, but competitive drug is far less appealing and effective. BOT drug is a new standard and as the example in Japan competition sells 8x less then what BOT drug does. Qbxa is close competitor selling 8x less in Japan.

4. What is expected sales?

Since it is covered by insurance in US, the pricing will be similar to other drugs but our drug is far superior in effectiveness and ease to use.
The prescribtion will cost approx usd 700 ( most covered by insurance) and will last 1 month.
In Japan our sales growth is 60% YoY and as of today our partner Kaken sells close to 200 000 prescribtions.
US has 2.5x larger population.
W e can assume that in US withing 2 years we can sell at least 200 000 prescribtions, giving us revenue of usd 210 mln....again growth is double digit and in Japan on a second year of launch we still grow 60% YoY.
In Japan we already penetrated 3% of the market.

5. How does drug work and how serious is the Sweat problem?

Drug works by applying on your skin , like you would apply a roller refresher. Molecules go to your blood stream and prevent you from excessive sweating.
About 3% of US population suffer from excessive sweating. There is even society in US helping people with this illness.
It is classified as the illness and up till today there is no compelling drug in the market which provides safety, effectivenes and efficiency.

6. How much does it cost to manufacture and what would be gross margin?

Cost to manufacture will be no more then usd 60 per prescription and distribution cost up to 20%.
This will provide healthy gross margin of at least 70%

7. What are other ASX FDA approved comparable?

NEU. NEU has recently approved drug but fully gave it away for upfront payment usd 100mln plus royalties going forward.
it is expected that Royalties will be approx. Usd 30mln to 50mln p.a. .
Generally , FDA approved company has market cap of 14x of Sales or over 45x of Ebita